Calithera Biosciences, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (15)

Latest Posts

About This Stock More About This Stock
2 Names To Consider In A Heating Up Small-Cap Biotech Sector
Article By: Scott Matusow
Wednesday, November 27, 2019 8:30 AM EDT
The biotech sector has been heating up due to an increased risk appetite coming from additional market liquidity and a favorable Fed policy. Here, we highlight 2 early-stage biotech companies that we think can provide substantial upside.
In this article: CALA, CRIS Also: INCY, PFE, AZN, CNST, KRTX, NXTC
Read
Calithera Bioscience Shares Surge After Fast Track Designation Status
Article By: TickerTV
Wednesday, April 18, 2018 3:40 PM EDT
Shares of Calithera Biosciences, Inc. gained $0.60, or $9.45% during premarket trade on Wednesday.
In this article: CALA
Read
Calithera Pharma In Focus, Part 3 - Arginase Inhibitor And Acquisition Target
Article By: Scott Matusow
Monday, January 9, 2017 7:51 AM EDT
In the last part of our series on Calithera Biosciences we will be examining the company's second clinical asset and its acquisition chances sometime this year or early 2018.
In this article: CALA Also: GILD, BMY, AMGN, FPRX, AFMD
Read
Calithera In Focus, Part 2 - Upcoming Catalysts In TNBC And RCC
Article By: Scott Matusow
Wednesday, November 23, 2016 11:45 AM EDT
In this article, we will review Calithera's upcoming data catalyst value drivers, which should positively effect the company's market capitalization moving forward. Calithera is also poised to eventually become a high value acquisition.
In this article: CALA Also: BMY, MRK, NVS, RHHBY, CELG, AGIO
Read
Calithera Pharma In Focus, Part 1 - Checkpoint Inhibition
Article By: Scott Matusow
Wednesday, November 16, 2016 7:21 AM EDT
Clinical stage company Calithera presents an early stage investment opportunity with the ability to enhance therapeutic value to the first wave of IO therapeutics checkpoint inhibitors from Merck's Keytruda and Bristol-Myers Squibb's Opdivo.
In this article: CALA Also: AFMD, BMY, FPRX, BLUE, KITE, AZN, MRK, PFE, ADAP
Read

PARTNER HEADLINES

Latest Tweets for $CALA

No tweets yet!